Cargando…

Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease

OBJECTIVE: The SENSCIS(®) trial demonstrated a significant reduction of lung function decline in patients with SSc-associated interstitial lung disease (SSc-ILD) treated with nintedanib, but no significant effect on health-related quality of life (HRQoL). To assess whether SSc/SSc-ILD severity and l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreuter, Michael, Hoffmann-Vold, Anna-Maria, Matucci-Cerinic, Marco, Saketkoo, Lesley Ann, Highland, Kristin B, Wilson, Hilary, Alves, Margarida, Erhardt, Elvira, Schoof, Nils, Maher, Toby M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910566/ https://www.ncbi.nlm.nih.gov/pubmed/35640959 http://dx.doi.org/10.1093/rheumatology/keac325

Ejemplares similares

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment
por: Bruni, Cosimo, et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Healthcare Resource Utilization Among Patients in England with Systemic Sclerosis-Associated Interstitial Lung Disease: A Retrospective Database Analysis
por: Gayle, Alicia, et al.
Publicado: (2020)

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial
por: Denton, Christopher P, et al.
Publicado: (2022)

Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis
por: Kreuter, Michael, et al.
Publicado: (2022)

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial
por: Volkmann, Elizabeth R, et al.
Publicado: (2022)

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial
por: Seibold, James R, et al.
Publicado: (2020)

Fatum Inexorabile: Do Monocytes Predict the Fate of Interstitial Lung Abnormalities?
por: Kreuter, Michael, et al.
Publicado: (2022)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Interstitial lung disease in systemic sclerosis: where do we stand?
por: Cappelli, Susanna, et al.
Publicado: (2015)

Predictors of progression in systemic sclerosis patients with interstitial lung disease
por: Distler, Oliver, et al.
Publicado: (2020)

Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review
por: Matteson, Eric L., et al.
Publicado: (2023)

Lung Ultrasound B-Lines in the Evaluation of the Extent of Interstitial Lung Disease in Systemic Sclerosis
por: Bruni, Cosimo, et al.
Publicado: (2022)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Serum B-cell activating factor and lung ultrasound B-lines in connective tissue disease related interstitial lung disease
por: Wang, Yukai, et al.
Publicado: (2022)

Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review
por: Wang, YuKai, et al.
Publicado: (2017)

Management of Fibrosing Interstitial Lung Diseases
por: Maher, Toby M., et al.
Publicado: (2019)

The Role of Bronchoalveolar Lavage in Systemic Sclerosis Interstitial Lung Disease: A Systematic Literature Review
por: Orlandi, Martina, et al.
Publicado: (2022)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases
por: Wang, Yukai, et al.
Publicado: (2021)

Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis–Interstitial Lung Disease: A Systematic Review
por: Landini, Nicholas, et al.
Publicado: (2022)

Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects
por: Maher, Toby M., et al.
Publicado: (2022)

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
por: Nakshbandi, Gizal, et al.
Publicado: (2021)

The role of precision medicine in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review
por: Campochiaro, Corrado, et al.
Publicado: (2022)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2018)

Interstitial lung disease:  course report
por: Kreuter, Michael, et al.
Publicado: (2020)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
por: Fiorentini, Elisa, et al.
Publicado: (2022)

Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group
por: Adler, Sabine, et al.
Publicado: (2018)

Effect of Nintedanib on Progression of Systemic Sclerosis‐Associated Interstitial Lung Disease Over 100 Weeks: Data From a Randomized Controlled Trial
por: Assassi, Shervin, et al.
Publicado: (2022)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2016)

Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders
por: Panagopoulos, Panagiotis, et al.
Publicado: (2021)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

Effects of nintedanib by inclusion criteria for progression of interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Interstitial lung diseases: course report
por: Kreuter, Michael, et al.
Publicado: (2019)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_38r52oum9kunbfvanoufu8ntov